Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial

Aydar A Ishmukhametov, Aleksandra A Siniugina, Nadezhda V Yagovkina, Vladimir I Kuzubov, Konstantin A Zakharov, Viktor P Volok, Maria S Dodina, Larissa V Gmyl, Natalya A Korotina, Rostislav D Theodorovich, Yulia I Ulitina, Andrey A Tsaan, Tatiana V Pomaskina, Anna V Kalenskaya, Irina V Solovjeva, Elena V Tivanova, Larissa Y Kondrasheva, Antonina A Ploskireva, Vasiliy G Akimkin, Ksenia A Subbotina, Georgy M Ignatyev, Anastasia K Korduban, Elena Y Shustova, Ekaterina O Bayurova, Alla S Kondrashova, Darya V Avdoshina, Anastasia N Piniaeva, Anastasia A Kovpak, Liliya P Antonova, Yulia V Rogova, Anna A Shishova, Yury Y Ivin, Svetlana E Sotskova, Konstantin A Chernov, Elena G Ipatova, Ekaterina A Korduban, Liubov I Kozlovskaya, Ilya V Gordeychuk
doi: https://doi.org/10.1101/2022.02.08.22270658
Aydar A Ishmukhametov
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
2Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleksandra A Siniugina
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadezhda V Yagovkina
3Kirov State Medical University of the Ministry of Health of Russia, Kirov, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir I Kuzubov
4Healthcare Unit No. 163 of Federal Medical Biological Agency of Russia, 630559, Novosibirsk region, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantin A Zakharov
5Eco-Safety Scientific Research Center, 196143, Saint-Petersburg, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viktor P Volok
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
6Lomonosov Moscow State University, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria S Dodina
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larissa V Gmyl
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalya A Korotina
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rostislav D Theodorovich
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yulia I Ulitina
7RIC-Pharma, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrey A Tsaan
7RIC-Pharma, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana V Pomaskina
8Biopolis-Kirov 200, branch of the Chumakov Center for Research and Development of Immune-and-Biological Products, Kirov, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna V Kalenskaya
9Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina V Solovjeva
9Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena V Tivanova
9Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larissa Y Kondrasheva
9Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonina A Ploskireva
9Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasiliy G Akimkin
9Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 111123, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ksenia A Subbotina
10Perm State Medical University Ministry of Health of Russian Federation, Perm, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgy M Ignatyev
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasia K Korduban
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Y Shustova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterina O Bayurova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alla S Kondrashova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darya V Avdoshina
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasia N Piniaeva
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasia A Kovpak
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liliya P Antonova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yulia V Rogova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna A Shishova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
2Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yury Y Ivin
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Svetlana E Sotskova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantin A Chernov
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena G Ipatova
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterina A Korduban
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liubov I Kozlovskaya
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
2Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilya V Gordeychuk
1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia
2Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gordeychuk_iv@chumakovs.su
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in adult volunteers aged 18-60.

Safety of the vaccine was assessed in 398 volunteers who received two doses of the vaccine (n=298) or placebo (n=100). The studied vaccine has shown good tolerability and safety. No deaths, serious adverse events (AE), or other significant AE related to vaccination have been detected. The most common AE in vaccinated participants was pain at the injection site (p<0.05).

Immunogenicity assessment was performed in 167 volunteers (122 vaccinated and 45 in Placebo Group) separately for the participants who were anti-SARS-CoV-2 nAB negative (69/122 in Vaccine Group and 28/45 in Placebo Group) or positive (53/122 in Vaccine Group and 17/45 in Placebo Group) at screening.

At Day 42 after the first immunization the seroconversion rate in participants who were seronegative at screening was 86.9% with average the geometric mean neutralizing antibody (nAB) titer of 1:20. Statistically significant (p<0.05) increase of IFN-γ production by peptide-stimulated T-cells was observed at Days 14 and 21 after the first immunization.

In participants who were seropositive at screening but had nAB titers below 1:256 the rate of 4-fold increase in nAB levels was 85.2%, while in the participants with nAB titers >1:256 the rate of 4-fold increase in nAB levels was below 45%. For the participants who were seropositive at screening the second immunization did not lead to a significant increase in nAB titers.

In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with 86.9% seroconversion rates in participants, who were seronegative at screening. In participants who were seropositive at screening and had nAB titers below 1:256, a single immunization lead to a 4-fold increase in nAB levels in 85.2% cases.

Competing Interest Statement

A.A.I., A.A.S., V.P.V., M.S.D., L.V.G., N.A.K., R.D.T., G.M.I., A.K.K., E.Y.S., E.O.B., A.S.K., D.V.A., A.N.P., A.A.K., L.P.A., Y.V.R., A.A.S., Y.Y.I., S.E.S., K.A.C, E.G.I., E.A.K., L.I.K. and I.V.G. are employees at the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, which developed and manufactured CoviVac

Clinical Trial

NCT05046548

Funding Statement

Study was funded by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol (VKI-I/II-08/20) and its supplementary documentation were approved by the Ethics Committee of the Ministry of Health of the Russian Federation (No. 502 from September 21, 2020). Additionally, the protocol was approved by the local Ethics Committees of the clinical sites, namely Kirov State Medical University of the Ministry of Health of Russia [No. 13/2020 from September 28, 2020]; Healthcare Unit No. 163 of FMBA of Russia, [No.1 from October 11, 2020]; Eco-Safety Scientific Research Center [No. 157 from October 1, 2020]. The study protocol was registered at clinicaltrials.gov (ID NCT05046548)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of interest statement: A.A.I., A.A.S., V.P.V., M.S.D., L.V.G., N.A.K., R.D.T., G.M.I., A.K.K., E.Y.S., E.O.B., A.S.K., D.V.A., A.N.P., A.A.K., L.P.A., Y.V.R., A.A.S., Y.Y.I., S.E.S., K.A.C, E.G.I., E.A.K., L.I.K. and I.V.G. are employees at the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, which developed and manufactured CoviVac

  • Financial support: Study was funded by the Chumakov Federal Scientific Center for Research and Development of Immune-and- Biological Products of Russian Academy of Sciences.

  • ishmukhametov{at}chumakovs.su (A.A.I.), sinyugina{at}chumakovs.su (A.A.S.), volok_vp{at}chumakovs.su (V.P.V.), dodina_ms{at}chumakovs.su (M.S.D.), gmyl_lv{at}chumakovs.su (L.V.G.), korotina_na{at}chumakovs.su (N.A.K.), teodorovich_rd{at}chumakovs.su (R.D.T.), ignatjev_gm{at}chumakovs.su (G.M.I.), korduban_ak{at}chumakovs.su (A.K.K.), shustova_eu{at}chumakovs.su (E.Y.S.); bayurova_eo{at}chumakovs.su (E.O.B.), kondrashova_as{at}chumakovs.su (A.S.K.), avdoshina_dv{at}chumakovs.su (D.V.A.), pinyaeva_an{at}chumakovs.su (A.N.P.), kovpak_aa{at}chumakovs.su (A.A.K.), antonova_lp{at}chumakovs.su (L.P.A.), rogova_jv{at}chumakovs.su (Y.V.R.), shishova_aa{at}chumakovs.su (A.A.S.), ivin_uu{at}chumakovs.su (Y.Y.I.); sotskova_se{at}chumakovs.su (S.E.S.), chernov{at}chumakovs.su (K.A.C), ipatova_eg{at}chumakovs.su (E.G.I.), e.korduban{at}gmail.com (E.A.K.), kozlovskaya_li{at}chumakovs.su (L.I.K.), gordeychuk_iv{at}chumakovs.su (I.V.G.).

  • nad0511ya{at}rambler.ru (N.V. Y.);

  • msch163{at}fmbamail.ru (V.I.K.),

  • konstantin.zakharov{at}mail.ru (K.A. Z.),

  • tsaan{at}ric-pharma.com (A.A.T.); shevchik.u{at}gmail.com (Y.I.U)

  • tania16may{at}gmail.com (T.V.P.)

  • kalenskaya{at}cmd.su (A.V.K.), solovieva_iv{at}cmd.su (I.V.S.), tivan{at}cmd.su (E.V.T.), kondrasheva{at}cmd.su (L.Y.K.), antoninna{at}mail.ru (A.A.P.), vgakimkin{at}yandex.ru (V.G.A.)

  • ka.subbotina{at}bk.ru (K.A.S.)

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted February 09, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial
Aydar A Ishmukhametov, Aleksandra A Siniugina, Nadezhda V Yagovkina, Vladimir I Kuzubov, Konstantin A Zakharov, Viktor P Volok, Maria S Dodina, Larissa V Gmyl, Natalya A Korotina, Rostislav D Theodorovich, Yulia I Ulitina, Andrey A Tsaan, Tatiana V Pomaskina, Anna V Kalenskaya, Irina V Solovjeva, Elena V Tivanova, Larissa Y Kondrasheva, Antonina A Ploskireva, Vasiliy G Akimkin, Ksenia A Subbotina, Georgy M Ignatyev, Anastasia K Korduban, Elena Y Shustova, Ekaterina O Bayurova, Alla S Kondrashova, Darya V Avdoshina, Anastasia N Piniaeva, Anastasia A Kovpak, Liliya P Antonova, Yulia V Rogova, Anna A Shishova, Yury Y Ivin, Svetlana E Sotskova, Konstantin A Chernov, Elena G Ipatova, Ekaterina A Korduban, Liubov I Kozlovskaya, Ilya V Gordeychuk
medRxiv 2022.02.08.22270658; doi: https://doi.org/10.1101/2022.02.08.22270658
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Safety and immunogenicity of inactivated whole virion vaccine CoviVac against COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase I/II clinical trial
Aydar A Ishmukhametov, Aleksandra A Siniugina, Nadezhda V Yagovkina, Vladimir I Kuzubov, Konstantin A Zakharov, Viktor P Volok, Maria S Dodina, Larissa V Gmyl, Natalya A Korotina, Rostislav D Theodorovich, Yulia I Ulitina, Andrey A Tsaan, Tatiana V Pomaskina, Anna V Kalenskaya, Irina V Solovjeva, Elena V Tivanova, Larissa Y Kondrasheva, Antonina A Ploskireva, Vasiliy G Akimkin, Ksenia A Subbotina, Georgy M Ignatyev, Anastasia K Korduban, Elena Y Shustova, Ekaterina O Bayurova, Alla S Kondrashova, Darya V Avdoshina, Anastasia N Piniaeva, Anastasia A Kovpak, Liliya P Antonova, Yulia V Rogova, Anna A Shishova, Yury Y Ivin, Svetlana E Sotskova, Konstantin A Chernov, Elena G Ipatova, Ekaterina A Korduban, Liubov I Kozlovskaya, Ilya V Gordeychuk
medRxiv 2022.02.08.22270658; doi: https://doi.org/10.1101/2022.02.08.22270658

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (898)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8774)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1858)
  • Geriatric Medicine (178)
  • Health Economics (387)
  • Health Informatics (1288)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10549)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1750)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (963)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1842)
  • Public and Global Health (3977)
  • Radiology and Imaging (652)
  • Rehabilitation Medicine and Physical Therapy (343)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)